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Abstract
Evaluation of a Comprehensive Diabetes Mellitus Protocol at a Rural, Federally Qualified Health
Center in Southern West Virginia

Hannah Davis
Background: Diabetes mellitus is a chronic disease that affects nearly 34 million Americans. In
rural Appalachia, the population is affected disproportionately at a rate of 14% compared to the
national average of 10%. Diabetes is a lifelong, chronic condition managed best by a
multidisciplinary team-based approach to achieve optimal disease control. Best practices in the
care of diabetes support the use of evidenced based care protocols and leveraging technology to
decrease the burden of disease. Type 2 diabetes mellitus (T2DM) is the most common type,
making it the focal population for evaluation.
Purpose: The purpose of this project was to evaluate the impact of a standardized diabetes
mellitus protocol for patients with T2DM at a rural federally qualified health center (FQHC) in
rural southern West Virginia. Program evaluation completes the care cycle. This information can
inform stakeholders about a protocol’s effectiveness, thus leading to recommendations for
change to improve T2DM education and outcomes in healthcare delivery.
Intervention and Methods: Program Evaluation was completed using a retrospective chart
review and a provider survey. Objective 1 was to evaluate the diabetes protocol using seven core
quality measures (hemoglobin A1c, blood pressure, low density lipoprotein [LDL] cholesterol,
diabetes self-management education (DSME), annual urine microalbumin, retinopathy, and
neuropathy exams) over three years (pre-protocol T1 and post-protocol T2 and T3). Objective 2
utilized a provider survey to determine behaviors regarding Type 2 Diabetes Mellitus (T2DM)
protocol and diabetes education team awareness and utilization.
Results: Results for Objective 1 found statistically significant improvement at T3 for diastolic
blood pressure and annual microalbumin, but not for other metrics. Overall, most metrics noted
improvement or stabilization over all time periods despite the evaluation taking place during the
COVID-19 pandemic. Results for Objective 2 found that majority of providers were aware of the
T2DM protocol and utilized the diabetes education accreditation program (DEAP) team
regularly.
Conclusion: The evaluation provided valuable insight on the current efforts to reduce the burden
of diabetes mellitus at the facility in rural West Virginia. Over half of all core quality measures
met facility benchmarks, however measures for DSME referral, A1c, retinopathy and neuropathy
exams are still lower than expected. All providers agree that COVID-19 had a negative impact
on patient care. Recommendations for improvements in practice include a patient-individualized
approach to care with increasing utilization of the DEAP team, and continuous provider support
of DSME in the management of patients with T2DM.
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Background
Problem Description
Diabetes mellitus is a chronic disease that affects nearly 34 million Americans (Centers
for Disease Control and Prevention [CDCP], 2019a). Type 2 diabetes mellitus (T2DM) is the
most common form of diabetes; 90% of all cases are type 2. T2DM is defined as the decrease in
beta cell function that limits insulin production, or the decreased cellular response to insulin,
called insulin resistance (CDCP, 2019b). This leads to insulin deficiency and resultant
hyperglycemia, which when uncontrolled may result in increased morbidity and mortality.
The Problem of Diabetes Mellitus in WV
Diabetes affects individuals in rural Appalachia disproportionately; when compared to
the national average of around one in ten individuals, more than one in seven individuals
(approximately 15%) in West Virginia (WV) have a diagnosis of T2DM (National Institute of
Diabetes and Digestive and Kidney Disease [NIH], 2020; WV Department of Health and Human
Resources [DHHR], 2018). Diabetes is more prevalent among individuals over age 65 years,
persons that completed lower than a high school education, and those with an annual household
income of less than $15,000. It is estimated that diabetes costs an estimated $2.5 billion in WV
each year, which includes the costs of serious complications such as heart disease, stroke, kidney
disease, and amputations (Allen, 2019).
Attention must be paid to cultural nuances and external forces on the people of WV for a
thorough understanding of the population. The entire state of WV is in central Appalachia, a
rural mountainous region in the eastern United States. While rugged and beautiful, the economy
has been depressed for years with over 16% of West Virginians living below national poverty
levels (O’Leary, 2020). Median per capita income for West Virginia was $27,446 in 2019, about
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$8,000 lower than the national levels (US Census Bureau, 2020). Specifically in the local region
for this clinic, per median income is even lower at $23K. Overall, WV has one of the highest
high school graduation rates in the nation at 92% however; the rate of graduation for the county
of interest for this project is only 83%. Six percent of residents do not advance past the ninth
grade. (Open Data Network, 2018). Other healthcare and social disparities that contribute to a
higher burden of disease include a shortage of primary care providers, poor transportation
infrastructure, and housing, food, and financial insecurity (Beverely et al., 2020).
Culturally, Appalachians are typically described as very independent, close to nature and
with a deeply held belief in God. They are friendly, kind, and helpful, known for taking care of
the needs of others. Carpenter and Smith (2018) describe Appalachians as self-determined and
self-reliant. Appalachians also have a strong sense of what is right and what ought to be. They
have a deep mistrust of anyone who is new, or anyone who is identified as a stranger.
Appalachian culture is noted for resistance to change (Hilly, 2015). Understanding the social
factors and the strong influence of Appalachian culture on health, wellness and disease
management is important to improving population health.
Managing Diabetes with an Evidence-Based Protocol in a Primary Care Clinic in WV
Protocol driven care based on best practices has been shown to improve chronic disease
management. Protocols drive provider decisions, provide clear patient expectations, and prevent
morbidity and mortality (Kurdi, 2015). The ADA and the AACE are two expert bodies that
author clinical practice guidelines (CPG) to guide treatment. Updated periodically, these bodies
promote evidenced based, cost effective, cost efficient, patient centered care, delivered by a
multidisciplinary clinical team. The use of decision support tools and patient registries are
recommended to improve care. Diabetes self-management education programs (DSME) feature
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prominently in both CPG’s. Strategies are designed to reduce the morbidity and mortality of
diabetes, reduce the overall burden of disease, and maximize the patient’s health and functional
status. While care is delivered at the individual patient level, both groups recommend the use of
systematic data collection and monitoring of the entire diabetes population to better understand
how the larger population is being impacted. Said another way, does the health of the community
improve as the health of the individual improves? (ADA, 2020; AACE 2015). The clinic site of
this evaluation adopted a standardized protocol to direct the care of patients with diabetes, which
incorporates the American Diabetes Association (ADA) and American Association of Clinical
Endocrinology (AACE) elements (see Appendix A for detailed protocol). The diabetes protocol
at the facility was created with a focus on rural health with an understanding of the social and
cultural norms of the community it serves. This aided in the successful creation of a diabetes
program to improve the health and outcomes of patients in rural Appalachia of WV.
The clinic in this evaluation is a federally qualified health center (FQHC) facility located
in southern WV serving over 16,000 patients. The leadership team sought to improve the care
approach to more than 1,700 patients that have a diagnosis of T2DM. These patients had
suboptimal outcomes in numerous areas; in addition to uncontrolled diabetes, many had multiple
coexisting comorbidities such as cardiovascular and kidney disease. Initially, the agency did not
have a formal DSME program. Leadership was concerned not only for the health of their patients
and the greater community, but that these poor patient outcomes could lead to therapeutic inertia
in the clinicians. Karam et al (2020) characterize these care burdens as a failure to screen,
escalate treatments, make appropriate referrals, and manage risk factors and complications. For
these reasons, leadership felt compelled to devote resources that would improve the care of
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people with diabetes. The Chronic Care Model (CCM) was used to direct initial quality of care
program at the facility and will be discussed below.
Conceptual Model used for the Integration of the Evidence Based Diabetes
Evaluation and Management Protocol. The Chronic Care Model (CCM), developed in the
U.S. in 1990, was designed to restructure healthcare interactions, particularly regarding chronic
conditions, between health systems and communities. The aim of the CCM is to improve the use
of existing resources while creating new ones that allows improved health and empowered
patient interaction (Baptista et al., 2016). Current trends support aggressive screening for early
identification of disease and the use of team-based care such as that employed in the CCM
(ADA, 2018).
The CCM incorporates a proactive, evidence-based, and patient-centered approach to
care (Grover & Joshi, 2014). It is composed of intersecting components which are essential to
driving down the burden of chronic disease. These elements include integrating community
resources and policies, redesigning health care delivery, increasing self-management support,
leveraging clinical information systems to improve communication and patient engagement.
Evidence-based change concepts within each element, in combination, foster productive
interactions between informed patients, who take an active part in their care, and support
providers with resources and expertise. See Figure 1.
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Figure 1
Chronic Care Model (Wagner, 1998)

When used to guide diabetes care, the CCM has been attributed with decreasing patient
morbidity and mortality. Cardiovascular disease declined by 57%, microvascular complications
by 12%, and mortality by 66% (ADA, 2020). When used appropriately and in full context, the
CCM has promising implications for improving diabetes outcomes and cost savings of over
$7,000 per patient (ADA, 2020). The CCM, already in use at the facility, allows an exchange of
healthcare information between providers and patients, with a result being a higher degree of
patient engagement and better diabetes control.
The CCM incorporates traditional Appalachian values of independence and seeing
themselves as capable and able to direct their own health care. An individualized teaching plan
can be specifically adjusted to accommodate low literacy. When the care team is composed of
community members, their neighbors, and friends, who share the same values and disposition,
patients are more likely to make adjustments that promote a healthy lifestyle and control a
challenging disease such as diabetes.
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The Development of Diabetes Education Accreditation Program (DEAP) Team
Leading the Evidence Based Diabetes Evaluation and Management Protocol Integration.
The initial plan by the stakeholders of the facility was to create a diabetes work group that would
ultimately position the facility to achieve full accreditation as a DSME provider. The work group
led a small pilot study with a volunteer receiving DSME provided by one employee of the
agency over six months. The pilot needed to show improvement in at least two focus areas (ex.
weight loss, Hgb A1c improvement, etc.), which was achieved. The workgroup also completed a
Health Resources and Services Administration (HRSA) review that identified areas for
improvement in T2DM management. Numerous other data were collected including
demographics of the service population and the expected reduction in the burden of disease.
Capital resources and cost associated with startup of a DSME program were determined. The
impact on clinic flow was analyzed; the economic impact in terms of revenues to the facility was
projected. Steps to ensure sustainability were also identified. This work resulted in administrative
approval for the new program. National accreditation was granted in February 2018. (S. Ward,
personal communication, July 20, 2021).
With accreditation achieved, the diabetes provider team became the Diabetes Education
Accreditation Program (DEAP) leaders for the facility, and the membership was expanded in
accordance with CDC recommendations to include a certified diabetes educator (CDE), two
clinical pharmacists, an advanced practice nurse practitioner (APRN), and a registered nurse
(RN). At the recommendation of the facility Board of Directors, an oversight committee was
formed to provide ongoing management of patient care. This committee consists of the DEAP
team, a physician, the director of nursing (DON), a facility board member, and a community
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member. The DEAP established their mission: “To improve the education and care of diabetes
patients at the facility.”
The DEAP system intervention adopted a standardized protocol for the care of patients
with diabetes at the facility, drawn from the ADA (2018) and AACE (2015) clinical practice
guidelines. See Appendix A for the fully detailed outline of the standardized protocol, which is
approximately ten pages in length. Over a series of meetings, staff was educated on the protocol
and data storage in the electronic health record (EHR) for future data retrieval and program
evaluation. Patients and the greater community were informed of the new care approach via
flyers posted in the clinic and internet marketing. Following the successful pilot program, the
standardized protocol was formally implemented in January 2020 with integration as a linked
document into the EHR. Prompts were later installed into the EHR for a simplified referral
process for patients with a T2DM diagnosis.
Literature Review and Synthesis
This literature review is limited to the research on program evaluation and the metrics
commonly used to measure T2DM control. A comprehensive literature search was performed
using PubMed, Medline, and CINAHL from December 2020 through March 2021 using the
following question in Population, Intervention, Comparison, Outcome (PICO) format: How does
the adoption of a standardized diabetes mellitus protocol affect core quality measures for T2DM
patients, and provider perceptions over a two-year period (from January 2019 to December
2021)?
The databases were searched utilizing keywords from the PICO in addition to relevant
terms for core quality measures including self-management education, and terms relative to the
clinic setting including rural health and the chronic care model. The results yielded over 500
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articles for review. Articles were excluded if they were published before 2010, not of English
language, and if the article included persons less than 18 years of age. A total of over 40 articles
were reviewed and synthesized to compile a list of best practices for evaluating the provision of
care for patients with diabetes. Diabetes is a complex disease process that requires a
comprehensive medical approach for the management and prevention of its comorbidities. The
ADA Standards of Medical Care in Diabetes clinical practice guideline (2018) and AACE
clinical practice guideline (2015) support the use of a comprehensive medical evaluation to
confirm diabetes diagnosis, evaluate comorbidities, review treatments, and formulate a selfmanagement plan. From this thorough literature review and using the information from these
guidelines, best practices for diabetes care were evaluated and synthesized in the following
section into the categories of Screening and Diabetes Management.
Best Practices for Diabetes Care Synthesis
Screening. The first best practice in T2DM care begins with early recognition of at-risk
populations. Screening of diabetes in adult patients begins at age 45 and is repeated every three
years for those with normal findings (ADA, 2018). Screening should begin earlier if the patient
is overweight or obese with a body mass index (BMI) ≥25, or if Asian American a BMI ≥ 23,
and has at least one other additional risk factor such as: (a) maternal history of diabetes or
gestational diabetes (GDM) (b) family history of T2DM in a first or second degree relative, (c)
ethnic backgrounds (Native American, African American, Latino, Asian American, Pacific
Islander) or (d) insulin resistance (acanthosis nigricans, hypertension, hyperlipidemia, polycystic
ovarian syndrome, or small-for-gestational-age birth weight). Type 2 diabetes mellitus is
diagnosed by the confirmation of two abnormal screening tests on two different occasions. The
four accepted screening tests and diagnostic measures are:
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● Fasting plasma glucose ≥ 126 mg/dL
● 2-hour plasma glucose ≥ 200 mg/dL during oral glucose tolerance testing (OGTT)
● Hemoglobin A1C ≥ 6.5%
● Random plasma glucose ≥200 mg/dL, with classic symptoms of hyperglycemia;
polyuria, polydipsia, polyphagia
Once the diagnosis is confirmed, it is critical that the patient’s chart reflects a diagnosis
of T2DM. Accurate recording of pertinent medical facts ensures that the patient will have access
to proper monitoring and care.
Diabetes Management: Seven Core Measures. The following section describes the seven most
common core measures evaluated in this study per the ADA 2018 and AACE 2015 national
guidelines. These seven core measures review glycemic control, assess the provision of a selfmanagement plan through some form of diabetes education, evaluate for comorbidities, and
gauge treatment efficacy.
•

Hemoglobin A1c Monitoring and Management. Hemoglobin A1c is a test that
measures the amount of glucose attached to hemoglobin, which is the part of the
red blood cell that carries oxygen to the body (U.S. DHHR, 2020). Hemoglobin
A1c is an indirect measure of the glucose average over three months (ADA,
2018), which should be evaluated every 3 months for uncontrolled T2DM
patients, and every 6 months for controlled T2DM patients. This glucose measure
is widely utilized, due to its ease of use, lack of need for fasting, greater preanalytical stability, and less variations with illnesses. A hemoglobin A1c less than
7% reduces the risk of microvascular and macrovascular complications.
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•

DSME Utilization. The use of DSME improves care and decreases poor outcomes
(ADA, 2018). Although extremely successful, DSME can be limited in use due to
lack of knowledge, availability, and feasibility related to cost. Canada, Shah &
Booth (2009) found that DSME was utilized by only 25-30% of the T2DM
population. Lower use of DSME was noted for older adults, immigrants, people
with lower socioeconomic backgrounds, and individuals with other physical or
mental health conditions (Cauch-Dudek, Victor, Sigmond, & Shah, 2013). Poor
patient compliance with DSME were found to be related to decreased awareness,
scheduling conflicts, and inconvenient locations (Gucciardi et al., 2012). Primary
care providers also were found to have a low referral rate due to low awareness
and limited access (Gucciardi et al., 2011). Despite low DSME utilization,
Gucciardi (2020) reported on the successful use of onsite nurse-dietician led
education interventions, which resulted in a lowering of hemoglobin A1c.
Positive impact of DSME was described in a systematic review by Chrvala et al.
(2016). One hundred twenty papers, all randomized control trials, were included,
examining a broad variety of DSME interventions (118) and their associated
impact on A1c values. Nearly 70% of the interventions showed an improvement
in A1c values, specifically in persons receiving more than 10 hours of education
in a group setting having the best outcomes. Those with higher A1c values (>9
percent) had the most significant lowering with DSME. Nearly 84% achieved
reduction in A1c levels, further providing evidentiary support of DSME.

•

Blood Pressure Monitoring and Management. Blood pressure control is an
important step in preventing cardiovascular disease. Elevated blood pressure,
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specifically a sustained pressure over 140/90 mmHg, is a common comorbidity
found in uncontrolled patients with diabetes. Studies have shown a positive
relationship between insulin resistance and hypertension. When insulin levels are
high, the body retains salts and fluids, creating an increased vascular volume.
Over time the vessels become stiff, resulting in high blood pressure. Insulin
resistance and hypertension double the likelihood that the patient will go on to
develop cardiovascular disease (Jovinally, 2020).
•

Dyslipidemia Assessment and Control. Cholesterol is a naturally occurring
substance in the body, important to overall health. Lipoproteins include highdensity lipoprotein (HDL) (good cholesterol), low-density lipoprotein (LDL) (bad
cholesterol) and triglycerides. When cholesterol levels are too high, plaque builds
up on blood vessel walls, causing a narrowing or blockages. When combined with
hypertension, as discussed above, this dramatically increases the risk of
developing atherosclerotic cardiovascular disease (ASCVD) such as coronary
artery disease, chest pain, myocardial infarction, stroke, transient ischemic
attacks, and peripheral vascular disease (AHA, 2016). Elevated levels of (LDL)
cholesterol are directly linked to ASCVD (AACE, 2015). The burden of disease
related to dyslipidemia in WV is notable. The state has the highest rate of
myocardial infarction (7.5%) and coronary heart disease (8%) in the nation (WV
DHHR, 2018).
Increased LDL cholesterol is commonly seen in poorly controlled diabetes and is
related to a multitude of factors such as diet, elevated glucose, and adiposity
(AHA, 2016). High LDL is associated with poor outcomes in diabetes (AACE,
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2015). To improve outcomes and reduce progression of cardiovascular disease, a
lipid blood panel should be annually assessed in patients with diabetes with a goal
of achieving an LDL <100 mg/dl.
•

Urine Microalbumin or Albumin to Creatinine Ratio Testing for Diabetic
Nephropathy. Over time, poorly controlled diabetes contributes to a condition
called diabetic nephropathy, a decline in kidney function that often leads to
kidney failure. Decreased kidney function also plays a role in the development of
hypertension. Studies have shown that 9 in 10 individuals are unaware that they
have a diagnosis of chronic kidney disease (CDC 2019a). Furthermore, The
National Kidney Foundation (2016) has reported that 35% of all patients with
diabetes have chronic kidney disease; this is projected to increase to 50% by
2025. Dialysis is a mainstay treatment option for end-stage kidney disease, which
is not only costly but has a negative impact on quality of life. The average annual
cost for one year of hemodialysis is around $72,000 and about $53,000 for
peritoneal dialysis (Johnson, 2014).
Early detection of declining kidney function can be accomplished with urine
microalbumin testing, which looks at the albumin to creatinine ratio. This is an
easy to obtain test in the primary care setting. A normal albumin/creatinine ratio is
defined as less than 30mg/g (ADA, 2018). Treatment includes strict glycemic
control and the use of an angiotensin converting enzyme (ACE) inhibitor or
angiotensin receptor blocker (ARB) (ADA, 2018). Both the ADA and AACE
recommend annual microalbumin screenings.
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•

Foot Screenings for Diabetic Neuropathy. Uncontrolled diabetes can also lead to
the damage of peripheral nerves, resulting in impaired or complete loss of
sensation, typically in the feet. Loss of sensation can lead to ulcerations,
infections, and in some cases, amputations. Nearly 50% of patients will have
some form of diabetic neuropathy (Zimmerman, 2016). In 2010, 73,000 adults
with diabetes underwent amputation (McDermott, 2018). While foot screenings
for patients with diabetes have reduced amputations by over half in the last 20
years, the number of individuals with complications is still a concern
(McDermott, 2018). This high risk of complications, cost, and long-term care can
be positively impacted through foot exams.

•

Annual Dilated Eye Exam Screening for Diabetic Retinopathy. Overtime,
T2DM can cause damage to blood vessels in the eye due to hyperglycemia. It is
the leading cause of new cases of blindness in people ages 20-74 years; most of
these are preventable (Research to Prevent Blindness, 2016). It is estimated that as
many as 40% of T2DM patients on insulin and 24% of patients taking oral
hyperglycemic medications will develop retinopathy after five years
(Zimmerman, 2016). This number greatly increases to 84% and 53%,
respectively, after 15 to 19 years (Zimmerman, 2016). The annual diabetes eye
examination is key to early recognition of retinopathy (ADA, 2018).

Rationale for Study
The Healthy People 2030 initiatives align with the rationale of the evaluation to improve
the care of patients with T2DM. The Healthy People 2030 initiatives (U.S. Department of Health
and Human Resources [DHHR], 2020) recommend:

14
•

An increase in the proportion of people with diabetes who get formal diabetes
education, with a target goal of 55.2 percent.

•

An increase in the proportion of adults with diabetes who have a yearly eye
examination, with a target goal of 67.7 percent.

•

The reduction in the rate of foot and leg amputations in adults with diabetes with
a target of 4.3 percent.

The Healthy People 2030 initiatives and core quality metrics align with the facility’s
vision, philosophy, and the T2DM protocol. The facility’s philosophy is to provide patient care
that includes individual, family, and community wellness, regardless of payment in a rural,
underserved community (Rainelle Medical Center, 2020). The facility’s overarching goal is to
improve the health of the individuals with T2DM through care process change. The facility had a
goal to increase the number of T2DM patients who receive DSME, an annual retinal
examination, and annual diabetic neuropathy screenings to prevent complications. The
recommendations provide feasible and accurate goal setting when evaluating the current core
quality measure outcomes.
A project's strengths, weaknesses, opportunities, and threats (SWOT) analysis was
performed to provide the facility with a snapshot of the internal and external factors that may
help or harm this evaluation project (Appendix B). The strengths of the evaluation were multiple
including increased provider awareness and improved core quality measure outcomes via
protocol driven care. The evaluation was feasible and cost neutral that was supported by key
stakeholders. Weaknesses included lack of provider use of the standardized protocol with
resultant poor outcomes of CQM’s. Opportunities for improved care for patients with T2DM
were substantial. These included data driven support for T2DM program expansion, leading to
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improved patient access to care. This in turn reduced comorbidities related to T2DM and
improves population health. Threats to the evaluation included the COVID-19 pandemic, as this
has delayed the evaluation from 12 to 24 months. Diabetes education staffing was relocated to
other positions due to facility need and staffing shortages, creating a strain for DSME.
A Framework for Quality Improvement for System Level Change
This system evaluation study utilized the CDC Framework for Program Evaluation in
Public Health (FPEPH). Evaluation is defined as a systemic method that determines the
effectiveness of a program or service, based on specific criteria developed by stakeholders.
Program evaluation is infrequently utilized in most practices; however, it is a vital aspect to
program sustainability (Moule et al., 2017). While various metrics were identified to evaluate the
impact of the standardized protocol at the facility, the DEAP team did not expressly select an
evaluation model. Various evaluation models exist; one of the most well-known and studied
models is the CDC Framework for Program Evaluation in Public Health (FPEPH). Multiple
papers were reviewed applying this model to diabetes program evaluation. The author
recommended this tool to guide facility evaluation as it is easy to follow with proven results that
can effectively assist with strategy and program improvement.
The FPEPH uses a systematic six step approach to improve and account for public health
actions by steps that are useful, feasible, ethical, and accurate (Figure 2) (CDC 2017). A brief
synthesis of the activities conducted at the facility for each step are described in the evaluation
plan section.
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Figure 2
CDC Framework for Program Evaluation (CDCP, 2017).

FPEPH Step 1: Engage Stakeholders. The first step of FPEPH is the engagement of
stakeholders. Stakeholders include persons involved in program operations (sponsors,
administration, staff), those served or affected by the program (patients, communities, skeptics),
and primary users of the evaluation (CDCP, 1999). Stakeholder values and perspectives drive the
program from inception; without their consideration and engagement, a program may fail to meet
stakeholder expectations. The risks could be that evaluation results may be ignored, discounted,
or rejected.
FPEPH Step 2: Describe the Program. In the second step, the program is described in terms of
need, results, and resources needed for implementation. Program descriptions convey the mission
and desired outcomes of the program being evaluated (CDC, 1999). A clear and logical
description of the program, agreed on by all stakeholders, ensures that program evaluation results
will have maximal application. Specifically, program need, expected results, activities of the
program, resources needed, and context are considered. A logic model is often used to illustrate
the various components in this stage.
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FPEPH Step 3: Focus the Evaluation Design. In step three of the FPEPH, the design of
program evaluation is determined. The selected design should be useful, feasible, ethical, and
accurate (CDCP, 1999.) It must be efficient (easy to execute), evidence-based, and reflect the
highest priorities of the stakeholders. The evaluation metrics link program purpose and
stakeholder values. In this step, the methodology is determined by asking what data do we need
and how will we collect it? Other considerations in this phase include consideration of patient
safety and confidentiality, minimizing any patient risk.
FPEPH Step 4: Gather Credible Evidence. Compiling information for stakeholders is an
important aspect of evaluation. The goal of this step is to collect information that gives a rigor of
comprehensive evidence-based program evaluation. In addition to selecting metrics as described
in Step 3, it is essential to determine the statistical significance of the program evaluation and
how much data is needed to answer such questions. How big will our sample size be? What level
of confidence do we need? Is there adequate power to detect effect? For clinical and practical
significance, the stakeholders need to engage in the program evaluation from the design through
interpretation of the results and dissemination, as they lend credibility and increase the likelihood
results will be accepted. Engaging stakeholders are essential for successful program evaluation,
sustainability, and continuous improvement.
FPEPH Step 5: Justify Conclusions. Activities in this step consider what the findings mean and
their significance to the overall program. The results will guide stakeholders’ decisions on what
do with the results. For stakeholders to decide that the conclusions are justified, great care take
must be taken with the process of data analysis and synthesis. Statistical and clinical significance
will be determined. When the results align with stakeholder values and expectations,
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stakeholders are likely to accept the conclusions. Considerations in this step include discussing
bias, study limitations, and unexpected findings.
FPEPH Step 6: Ensure Use and Share Lessons Learned. Activities involved in the final step
of the evaluation model revolve around disseminating the results and creating mechanisms to use
the results. Stakeholders must ensure that the evaluation is adequately portrayed and share
lessons learned. Strategic work must be done in this phase, with special attention paid to not only
sensitively communicating the results, but to also with a consideration of how stakeholders
should translate the new information into practice. Steps must be taken to ensure that the results
are not misused. Involving stakeholders from the design of the study through dissemination will
enhance the positive outcomes of the program evaluation. Team-based and co-learning approach
through continuous quality improvement lens will prevent emotionally charged of declining
morale or inertia.
Specific Aims
The specific aim of this program evaluation was to lead the FQHC in rural, WV through
the first evaluation and quality improvement (QI) project of their standardized approach to the
care of people with T2DM, with a focus on population health, identifying program/care strengths
and gaps, and informing future practices for the agency. Two primary objectives were identified
to be explored.
Objective 1: Are there significant differences on core quality measures (hemoglobin A1c, B/P,
LDL, DSME, annual microalbumin, eye exam and foot exam) between baseline (2019) and 1and 2-years follow-up (2020, 2021)?
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Objective 2: What are the perceptions and acceptability of the DEAP team as measured by the
provider questionnaire? What are the recommendations from providers to improve the
management of T2DM at the facility?
Methods
Context
The facility’s T2DM evidence-based protocol had not been formally evaluated since
implementation of the protocol. After having the protocol in place for two years, a formal
program evaluation is timely to evaluate whether the protocol needs revision to meet the needs of
the staff and an underserved population of patients with T2DM in rural Appalachia. This is the
first evaluation after implementation of a T2DM protocol and DEAP team to provide high-level,
evidence-based practices to the rural area. These services were previously not available or were
limited in access to patients in the community and surrounding areas. The results of the study
will be used for future continuous quality improvement.
Timeline for the T2DM Protocol Program Evaluation Study
An evaluation of the current diabetes protocol was completed in the spring of 2022. This
program evaluation project was the culmination of doctoral work for a nursing practice degree
that exemplified an area of interest by a clinic staff provider supportive of the T2DM protocol
and the work of the DEAP team. The following timeline and description of activities are as
follows:
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Time
Fall 2020-21

January 2022

February 2022
March 2022
April – May 2022
Summer 2022

Task
Engagement with FQHC stakeholders to
explore the potential for T2DM Protocol
Program Evaluation
WVU Institutional Review Board (IRB)
approval for the DNP Program Evaluation
study
Chart Review completed
Provider survey completed
Data analysis completed
Data write up and presentation

Interventions
This program evaluation study used a retrospective chart review one-group pretest–
posttest design to determine the effects of the DEAP intervention on the measures outlined in
Objective 1. The benefit of this design is justifiable when only one group of participants (T2DM
patients) is available and when creating a control group is not possible or unethical (Creswell &
Creswell, 2017). A cross-sectional survey was used to address Objective 2 to determine provider
behaviors related to the T2DM protocol and DEAP use.
Study Participants
Inclusion Criteria.
Objective 1
(1) Patients with a diagnosis of T2DM (ICD-10 code - type 2 diabetes mellitus), non-pregnant,
between the ages of 18 and 75, having at least one primary care visit for the treatment of T2DM
in the three periods (2019, 2020, and 2021)
(2) Eligible clinic providers included those family practice physicians, physician assistants
(PAs), or nurse practitioners (NPs) that were full-time primary care clinicians were employed by
the facility during the entire time frame of the study.
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Objective 2
All providers, regardless of type or status, were invited to complete the survey regarding
behaviors on T2DM protocol and DEAP use with recommendations for T2DM management.
Exclusion Criteria.
Objective 1
Pediatric clinicians were excluded, as their patient population does not meet age related inclusion
criteria. Nephrology patient data was also be excluded due to its subspecialty population and
inclusion of patients outside of the facility. Chart review exclusions also included pregnancy,
deceased patients, and type 1 diabetes mellitus codes.
Objective 2
Pediatric and subspeciality providers were also excluded from the provider survey.
A total of five physicians and three PAs met inclusion criteria and the retrospective chart
review was planned for charts completed by these specific providers. Patient care data from the
team champion nurse practitioner was excluded to minimize bias. Twenty-seven providers
received an email for the anonymous survey.
Setting
The protocol evaluation was conducted at a FQHC facility in rural WV. The
implementation of the protocol served as an educational intervention for family practice
providers to guide care to over 1,700 T2DM patients at the facility. This project was determined
to be congruent to the facility’s strategic plan to improve the care of patients with T2DM by
utilizing an evaluation model including 7 CQM’s and a provider survey.
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Budget
Evaluation of the T2DM protocol was budget neutral and was affordable. The work of
the doctoral student, including conducting program evaluation, represents no additional cost to
the agency. The student is not a member of the DEAP team; however, as a provider her
compensation included administrative time for QI projects. Data collection, retrieved by the
student represents a usual and customary function of this department. Appendix D outlines
estimated costs including the hourly wage of the team champion nurse practitioner and DEAP
staff members during meeting times and data collection. Much further downstream are potential
cost savings expected to result by reducing the burden of disease.
Evaluation Plan
Operationalizing the FPEPH
As noted previously, the FPEPH model was used to structure this program evaluation.
Each step of the framework was systematically operationalized to assess whether the T2DM
Protocol at the FQHC was effective based on the specific criteria of the objectives noted above.
A brief synthesis of the activities conducted at the facility for each step are described in the
following section.
FPEPH Step 1: Engage Stakeholders
Facility stakeholders were greatly concerned for the health status of those with diabetes,
their families, and the larger community. They valued providing care that was highly
individualized, using a team approach with community partners. They wanted to reduce the
burden of disease and improve the client’s functional status. Persons served by the program also
shared this value. Patients with diabetes wanted to feel good, be able to work and enjoy activities
with family and friends. They wanted to live longer, eat better, and spend less money on health
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care. They wanted to take fewer medications and spend less time in doctor’s offices and
hospitals. They valued knowledge and the skills to be able to care for themselves. The users of
the evaluation results value a cost-effective, cost-efficient delivery system. An investment in
resources to improve the health of this specific population could yield a high return, reducing
costs associated with chronic disease. A well-run efficient diabetes program could elevate the
status of the facility in the community, demonstrate their care is evidenced based, increase
sources of funding based on high quality care, possibly free up resources to develop programs for
other disease states, and increase provider job satisfaction.
The key stakeholders involved in the T2DM protocol evaluation included: The team
champion nurse practitioner, DEAP providers, advisory committee, administration, primary care
providers, support staff (i.e., nursing), information technology (IT), patients, and members of the
doctoral capstone committee. The specific stakeholders involved in the aims and results of the
evaluation are the administrators, DEAP team, and advisory committee.
The team champion nurse practitioner led the initial discussion for protocol evaluation
with the DEAP team in October 2020. This work group was primarily responsible for conducting
the evaluation. The evaluation produced two important pieces of information. It provides
information regarding the health of the facility’s patient population before and after adoption of
the standard protocol. It also provides opinion information about the providers who utilize the
standardized protocol. With these main objectives in place, the author engaged additional
stakeholders in the agency, including the Chief Executive Officer (CEO). Full approval was
received in January 2021, to proceed with no adjustments being made (Appendix E).
The process used for data retrieval was established during a meeting in late 2021.
Originally, there was a plan to pull data after 12 months of data. However, due to confounding
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factors of the COVID-19 pandemic, a cumulative report of 12 and 24 months of data will be
analyzed. The team leader extracted the initial report from the data analysis base, AZARA, and
then used a manual chart review from the EHR for 12- and 24-months’ data. The author created
the provider survey with assistance from the DEAP team and members of the doctoral capstone
committee. The team champion nurse practitioner worked with IT to create an emailed survey
for provider questionnaire disbursement using Qualtrics. The team champion nurse practitioner
led regular meetings with the DEAP team starting in January 2022 for data collection and
analysis. The team discussed CQM’s and provider questionnaire outcomes. The team overseen
all evaluation operations and communicated updates to stakeholders.
FPEPH Step 2: Describe the Program
The standardized protocol adopted for the facility was drawn from clinical practice
guidelines produced by experts in the field (See Appendix A for standardized protocol). Many
patients with T2DM did not enjoy optimal control of their diabetes and suffered significant
consequences in the form of co-morbid diseases, creating program necessity. The expected
results were better disease management, and a more engaged, self-sufficient patient population.
Resources, human and technical, were in place and are easily allocated. There was energy and
enthusiasm to create a new way of doing things. The DEAP team looked forward to a much more
visible role in the care of patients with diabetes; providers welcomed additional support in the
care of complex patients. Figure 4 illustrates a logic model of the diabetes program at the facility,
its inputs, activities outputs and goals.
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Figure 4
Protocol Logic Model

Over the course of several meetings in late 2019, a DEAP provider and medical director
wrote the standardized protocol to guide the care of persons with T2DM (S. Ward, personal
communication, July 20, 2021). The DEAP team provided a written copy of the typed
standardized to providers during a routine meeting in late 2019. The standardized protocol is not
currently housed within the electronic health record (EHR). The standardized protocol is divided
into three diagnostic groups (type 1, type 2, and pre-diabetes); however, T2DM was the focus of
this evaluation. Providers can review the standardized protocol with major themes of care
including:
•

History and physical

•

DSME

26
•

Pharmacologic management

•

Biometrics (A1C, BP, LDH)

•

Preventive health screenings (vaccines, foot exam, eye exam, etc.)
The protocol is accessible to all providers via an emailed, typed form. The seven core

quality measures provide objective data in evaluating outcomes. All providers have been
oriented to the standardized protocol with an expectation of its use to guide diabetic patient care.
DSME is one facility core quality measure that is of particular importance due to the referral
process. Providers are urged, but not required to refer all T2DM patients to the DEAP team for
DSME. Referral reasoning may include but are not limited to uncontrolled diabetes, new-onset
diabetes, change in medication, need for diet and exercise education, or annual follow-up.
Referrals are submitted electronically in the EHR. Patients not affiliated with the facility are also
eligible for DSME care; however, these patients are excluded from the program evaluation. The
patient’s last chart notes and reasoning of referral is sent to the DEAP receptionist for
scheduling.
Once admitted for DSME, the patient is invited to six individual visits over 3 months.
The educational content is standardized, reflecting care recommendations from specialty groups
and national guidelines. The DEAP providers can make recommendations to the patient’s plan of
care, communicated electronically with the referring provider. The provider has the final
decision regarding changes in patient management. Common care recommendations from the
DEAP team include medication adjustments, use of continuous glucose monitoring (CGM), as
well as reminders for scheduled screenings.
The seven core quality measures are objective; however, analyst interpretation may vary
results. We know that Hgb A1C, LDL, urine microalbumin, and dilated retinal and neuropathy
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exams each have acceptable test reliability and validity. These tests use physiologic metrics
commonly used to measure diabetes control. However, patients may not comply with testing and
referral recommendations. If we are unable to demonstrate an improvement in any of these
metrics, it may speak more to patient behaviors or challenges accessing specialists rather than as
a limitation of the test itself.
Blood pressure is influenced by multiple factors including technique, clinician
interpretation, time of collection, and patient factors such as anxiety. The program evaluation
cannot currently average readings for a cumulative percentage. Diabetes education in the
patient’s chart may also be subject to variations based on provider documentation and EHR
retrieval. By establishing limitations, the team champion nurse practitioner and stakeholders can
better understand the evaluation metrics and associated outcomes.
FPEPH Step 3: Focus the Evaluation Design
The aim of the facility was to improve the care of patients with T2DM. A comprehensive
team-based approach was adopted, and it was determined the standardized protocol would best
be measured by collecting specific quantitative data. While literally hundreds of metrics could
have been chosen for the first evaluation cycle, seven core measures provide a reasonable
snapshot of the population. Aggregate data was extracted from the electronic health record. This
represents an efficient use of time. The student and team leader of the evaluation team was
proficient at running data reports. The project lead had the support of a statistician and SPSS
software to conduct data analysis. As evaluation drew nearer, some stakeholders wanted to learn
more about the clinicians charged with delivering the care. They decided to add an electronic
survey to the evaluation design, collecting quantitative data on thoughts and beliefs regarding the

28
use of a standardized protocol. The quantitative data was easily retrieved from the EHR; the
provider survey was delivered via email and manually processed.
To narrow the evaluation, we will discuss utility, feasibility, propriety, and accuracy. The
four standards that were used to guide the 6-step program evaluation were utility, feasibility,
propriety, and accuracy.
Utility. Utility discerns what stakeholders need from the evaluation and how it will be used. The
purpose of the evaluation of the T2DM protocol is to understand the impact of a standardized
approach to care on patient population health. Biometric measures informed the facility on the
health of the population. Care gaps were identified, and data driven decisions can be made
regarding program priorities. Clinician perspectives were appreciated and incorporated to
strengthen how care is provided.
Feasibility. Feasibility involves cost, time, and skill needed to complete the evaluation. Cost for
the evaluation is minimal, as the DNP student and team leader involved in the evaluation project
was based on regular salary. Time spent in data collection and analysis was brief, as charts can
be directly pulled from AZARA and EHR. The data was analyzed using an ANOVA discussed
later in study design. The results are timely, as this will be the first evaluation completed after
the creation of the DEAP team and T2DM protocol within two years of creation. The skills
needed to complete the evaluation include basic EHR comprehension for chart review and email
use for provider questionnaires. Data analyzation skills include the use of an ANOVA at the
guidance of a statistician.
Propriety. Propriety determines who needs to be involved in the evaluation. The team champion
nurse practitioner will lead the evaluation. The faculty of record serves to guide the evaluation
and provide feedback. The content expert led the discussion on diabetes in rural Appalachia.
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The preceptor served as a clinical liaison and DEAP member for the diabetic community. The
statistician was able to aid in analysis of core quality measures and provider questionnaires for
accurate and meaningful data. Stakeholders were involved in results to provide feedback for
future evaluations and DEAP use.
Accuracy. The final component, accuracy, defines what evaluation will lead to accurate
information. Each of the standards serve an important role in focusing the evaluation of the
T2DM population. Accuracy was achieved by creating modifiers, utilizing data reporting
systems that can pull entries correctly from the corresponding EHR, and by setting statistical
significance parameters for analysis. Transferring accurate data into SPSS software led to
reliable conclusions on T2DM patient management.
FPEPH Step 4: Gather Credible Evidence
The sample size of T2DM patients at the facility for objective 1 included 168
randomized patients. Patient demographics, inclusion, and exclusion factors were based on
national ADA 2018 and AACE 2015 clinical guidelines. A probability value (p-value) is a
number describing how likely the data is true or occurred by random chance. The p-value is
considered statistically significant if the value is less than or equal to 0.05% (McLeod, 2019).
This p-value is used in the study to provide reliable and statistically relevant results. Systematic
random selection of the medical record reviews reduced selection biases and enhance credible
results. The facility evaluation gathered credible evidence from multiple sources. We compared
evidence-based core quality measures collected prior to the adoption of the standardized protocol
and after two years of use for objective 1. The evaluation also included provider responses to an
electronic survey composed of Likert style questions and open-ended questions as previously
discussed for objective 2.
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Data Collection Procedure. For Objective 1. This proposed study used a retrospective
chart review to collect seven core quality measures across three periods (Baseline (2019) and 2
years follow-up of post T2DM protocol and DSME implementation at T2 (2020), and T3 (2021).
Sample Size Estimation. Patients ‘medical records were reviewed using a data analytics
and quality improvement reporting module, AZARA, and the EHR for data retrieval. AZARA
was used to input inclusion and exclusion data for each of the eight providers. From the sample
size, 21 patients were randomly selected by simple randomization of every other chart. Each
medical record number was then de-identified using case ID such as 001, 002, etc. The case ID
was utilized for manual chart review to follow the patients forward in T2 and T3. Repeated
measured Analysis of Variance (ANOVA) for 7 outcomes variables with 3 repeated measures
(baseline, T2, and T3), using G*Power v.3.1.9.7 on repeated measure ANOVA were conducted.
Given α=0.05, moderate effect size (0.25), power of 80%, for 7 outcomes with 3 measurements,
correlation among repeated measures (0.50), a sample size of 168 was required.
Numerical data including Hgb A1c, blood pressure, and LDL was collected using the
patient’s most recent level collected during each period. Diabetes self-management education,
retinopathy, nephropathy, and neuropathy exams were reported by a positive or negative finding
in the chart for the specified periods. The evidence was safeguarded by using a discrete provider
login to the EHR and AZARA, so protected health information (PHI) is controlled, and all
Health Information Portability and Accountability Act (HIPAA) rules apply. Data collection was
completed by the DNP student. An example of the medical record review can be found in
Appendix F.
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Step 5: Justify Conclusions
The DNP student engaged stakeholders in data analysis to interpret findings based on
clinical significance. A statistician aided in determining statistical significance with use of SPSS
software. Data was easily interpreted by using percentages for change. Based on findings and
review of studies regarding diabetes education in similar populations, conclusions can be drawn
to lead future implications. Stakeholders can then decide how to proceed with changes in T2DM
care to foster improved outcomes in keeping with facility benchmark goals and national
guidelines. Results that align with the overarching goal of the facility and the DEAP team,
conclusions are likely to be accepted as accurate. Reviewing the limitations of the study sample
(rural, elderly, and underserved population) and missing data were essential for justification of
conclusions. The results will be used for future continuous quality improvement projects.
Step 6: Ensure Use and Share Lessons Learned
Dissemination of results of this program evaluation is being planned in multiple ways
beginning with a meeting with administration and eventually continuing to include all members
of the agency. Conclusions drawn based on data analysis will aid in making key global
recommendations based on the findings. It will, however, be at administration’s discretion to
guide us in releasing the results, whether this will be staged or in entirety. Process changes will
lie with the DEAP team and specific parties they deem essential to setting priorities, modifying
care pathways, delivering continued training, and so forth.
The DNP graduate student reported findings to the DEAP team monthly, or more
frequently as necessary. One or two scheduled meetings are being made to disseminate results to
stakeholders. Due to COVID-19 restrictions, these meetings may take place in the form of video
conferencing or via emails. Slide presentations and print literature may be used to convey the
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results of the program evaluation. Full dissemination of results take place in late summer of
2022.
In summary, the CDC FPEPH provides a useful roadmap to evaluate the adoption of a
standardized approach to T2DM care at the facility. It is easy to follow and allows for accurate
assessment and reliable results.
Measures
Objective 1
The measures for Objective 1 included core quality measures per clinical guidelines
(ADA, 2018; AACE, 2015). See Table 1. These core quality measures evaluated at the facility
are relevant and have been agreed upon by the DEAP team and advisory committee. All the core
measures in Aim 1 have been used with patients with T2DM populations. These have published
mean scores/SDs identifying clinically significant differences and are sensitive to compare
change over time.
Table 1
Facility Core Quality Measures
Core Quality Measures
Average hemoglobin A1C <7%
Documented self-management counseling
within the last year
BP controlled <140/90
LDL <100mg/dL
Yearly microalbumin
Dilated eye exam in the past year
Comprehensive foot exam documented at
all routine follow-up appointments

Percentage of
Compliance
50%
50%

Type of Data

50%
50%
50%
50%
85%

Continuous
Continuous
Dichotomous
Dichotomous
Dichotomous

Continuous
Dichotomous
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Objective 2
An anonymous survey with open-ended questions data was collected via an electronic
survey sent to all provider via secured Qualtrics. The survey questions included a 5-point Likert
scale and binary response of yes or no. Two open-ended questions were used to solicit providers’
perceptions on COVID-19 negative impact to diabetes care management and obtain
recommendations on how to improve the management of T2DM patient care in the facility and
rural community (Appendix C). The questionnaire was created using a Qualtrics survey. The
provider questionnaires were sent using an encrypted, safe browser at the facility with an
opening description of the survey (Appendix G). Total time for providers to complete the
anonymous survey questionnaire was between 10-20 minutes. Completion of the survey
indicated voluntary participation. Qualtrics data were converted into SPSS (version 28) for
analysis.
Quality Assurance and Data Integrity Techniques
Methods employed for assessing completeness and accuracy of data included data
management protocol and an audit trail of the data management procedures (Roberts et al., 1997;
Wynd & Schmidt, 2003). Other data integrity techniques included developing guides for
verification of missing data, coding each subject’s data, analyzing for data distribution, and
meeting statistical assumptions and any need for transformations prior to quantitative analyses
(Keppel & Wickens, 2004). Dr. Wang, biostatistician, was able to guide the quantitative data
management procedures and statistical data analysis. All quantitative data was cleaned to
identify outliers, data entry errors, or missing values.
Missing data was identified and reported. Rules for managing missing data were
discussed with our biostatistician to distinguish types of missing data (Mack et al., 2018; Musil
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et al., 2002). Using Qualtrics in the provider survey helped to control ranges and options and to
diminish missing data. Data conversion from Qualtrics to SPSS/SAS was conducted for analyses.
Data Analysis
Objective 1
Data analyses were conducted using the SPSS, version 28. Descriptive analysis was
conducted on patient’s’ demographic data retrieved from medical record review. A repeated
measures ANOVA with a Greenhouse-Geisser correction was used to compare means scores
differences of continuous variables (H1C, LDL, systolic BP, and diastolic BP) among baseline,
T2 and T3 time points. Once the main within-subject analysis was found, it was compared for
statistically significant difference (p < .05). Friedman ANOVA, a non-parametric multiple
groups comparison was used to analyze categorical or binary variables among baseline, T2 and
T3 time points. Post-hoc analysis with Bonferroni correction for multiple time points
comparisons was conducted between each pair of time point.
Low-density lipoprotein (LDL) cholesterol was found to have some abnormal values
outside of the range very low <40 and/or very high >180. For such values an LDL calculator
called the Martin/Hopkins method was utilized (American College of Cardiology, 2020). This is
a personalized approach that is useful for calculating accurate results for numbers that may be
elevated or low due to triglycerides changes. This was used in placed of the Friedwald equation
and results were updated.
Objective 2
Descriptive statistics were used to summarize the demographic data, CCI, and the
proportion of response options for each provider survey question. Content analysis was used to
address open-ended questions from anonymous provider survey. Content analysis is commonly
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used to uncover opinions important to the study participants (Krippendorf, 2004). This type of
analysis can identify the meaning and relationships of words or concepts. An audit trail was
maintained throughout the analysis process detailing key decisions undertaken by the researchers
(McBrien, 2008). The direct quotes did not contain individual names, and all information is
summarized without identifiers. Two members of the research team (DNP student and Faculty of
Record [FOR]) conducted data analysis (Miles & Huberman, 1994). Credibility, dependability,
and transferability are measures to obtain the trustworthiness of qualitative content analysis
(Graneheim & Lundman, 2004). The trustworthiness of this study will be achieved by agreement
of study findings through extensive discussion or data saturation (when there is no topic to
discuss).
Ethical Considerations
The project was submitted and approved by the institutional review board (IRB) in
January 2022, under the exempt category. The study used retrospective data in the medical
records. All data reports were de-identified and provider responses were anonymous. All data
were de-identified using case ID such as 001, 002, etc. In addition, the survey data was collected
anonymously via Qualtrics at the convenience of the participants. The completion of the
questionnaire indicated a willingness to participate in the study. No patients or providers were
contacted throughout the study, thereby not violating human privacy rights. Data collection and
data management was completed by the DNP student and supervised by the FOR and statistician.
Results
Objective 1. For the core quality measures scores (as measured by average hemoglobin A1c;
self-management counseling; blood pressure; LDL cholesterol; yearly microalbumin; eye exam,
and foot exam) between baseline (2019) and 2 years follow-up (2020 and 2021) scores, the
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results will be shared using descriptive statistics for patient demographics and the Charlson
Comorbidity Index (CCI).
Patient Demographics
There were 168 chart review completed at baseline. Of 168, 67 (39.9%) were males and
101 (60.1%) were females. The mean age was 60.54 (SD=12.02) years, ranges from 24 to 77
years. Average length of T2DM diagnosis was 5.72 (SD=3.40) years, ranged from 3 to 16 years.
Charlson Comorbidity Index (CCI)
The Charlson Comorbidity Index shows multiple comorbidities that can affect the care of
patients with diabetes. Of 168 patients, 68 (40.5%) had only on diagnosis of type 2 diabetes; 59
patients (35.1%) had one comorbidity; 25 patients (14.9%) had 2 comorbidities; 13 patients
(7.7%) had 3 comorbidities; 2 patients (1.2%) had 4 comorbidities, and 1 (0.6%) had 5
comorbidities. The most common comorbidities were 1. COPD 33 patients (19.6%); 2. CHF 12
patients (7.1%) and MI 12 patients (7.1%); 3. CVA/TIA 10 patients (6.0%); 4. Mild liver disease
9 patients (5.4%). Over 50% of patients with type 2 diabetes had multiple comorbidities. This
concludes the need for patient to have regular examinations and screenings to prevent related
comorbidities and provide adequate management of such processes.
Core Quality Measures
A repeated measures ANOVA with a Greenhouse-Geisser correction was used to
compare mean scores differences of continuous variables (H1C, LDL, systolic BP, and diastolic
BP) among baseline, T2 and T3 time points. The results of ANOVA are shown below. (Table 2)
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Table 2
Core Quality Measure (Continuous Variable) Results
Mean (SD)
Variables

A1C

Systolic BP

Diastolic BP

LDL

Range (Min-max)

Statistics
F (p value)

Baseline

Yr02

Yr03

(T1)

(T2)

(T3)

7.48 (1.64)

7.63 (1.81)

7.44 (1.55)

NS

5.00-13.70

4.50-14.00

4.70-7.44

(F=.92, p=.39)

128.55 (14.02)

132.25 (14.33)

128.87 (12.83)

***

92-164

100-180

100-182

(F=5.30, p<.01)

77.08 (8.75)

76.37 (8.61)

75.52

NS

58-104

54-96

50-102

(F=1.07, p=.35)

90.09 (37.48)

82.60 (38.62)

89.52 (40.05)

NS

23-234

12-217

19-306

(F=2.32, p=.12)

Table 2 Results Summary.
1) There were no significant differences for A1C across Baseline, T2, and T3 (F = .92, p =
.39).
2) There were significant differences on systolic BP across time points (F = 5.30, p <.01).
Post hoc analysis revealed that systolic BP was significantly increased from baseline to
Year 02 (128.55 mmHg to 132.25 mmHg, F=8.46, p < .01). There was no significant
difference between other time points. There were no significant differences for diastolic
BP across Baseline, T2, and T3 (F = 1.07, p =.35).
3) There were no significant differences for LDL across Baseline, T2, and T3 (F = 2.32, p
=.12).
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Next, using the core quality measures benchmark, the mean scores of these continuous variables
were grouped into 2 category/dichotomous variables. For example, A1C scores were grouped
into Group 1, = <50% and Group 2, = 50% and above; Systolic BP scores were grouped into
Group 1 = <140 mmHg and Group 2 = 140 mmHg and above; Diastolic BP scores were groups
into Group 1 = <90 mmHg and Group 2 = 90 mmHg and above; LDL scores were grouped into
Group 1, LDL = < 100mg/dL and Group 2 = 100mg/dL and above. Friedman Test, a nonparametric multiple groups comparison was used to analyze categorical or binary variables
among baseline, T2 and T3 time points. Post-hoc analysis was conducted to detect differences on
proportion of benchmark between each pair of time points (See Table 3).
Table 3
Core Quality Measures (Dichotomous) Results
Core

Percentage

Baseline

Yr02

Yr03

Statistics

Quality Measures

of

(T1)

(T2)

(T3)

(χ2, p value)

71 (48.3%)

56 (42.1%)

59 (44.7%)

NS

N=147

N=133

N=132

χ2 = 1.38 (p = .50)

126 (75%)

102 (72.9%)

114 (80.3%)

NS

N=167

N=140

N=142

χ2 = 2.80 (p =.25)

150 (89.8%)*

128 (91.4%)

138 (97.2%)*

**

N=167

N=140

N=142

χ2 = 7.0 (p =.03)

88 (62%)

94 (71.8%)

86 (65.2%)

NS

N=142

N=131

N=132

χ2 = 5.15 (p = .08)

8 (4.8%)*

37 (22%)*

25 (14.9%)

**

N=168

N=168

N=168

χ2 = 23.16, p < .001

Compliance
Average A1C <7%

50%

Blood pressure
Systolic BP <140 mmHg

Diastolic BP <90 mmHg

LDL <100mg/dL

DSME

50%

50%

50%

50%
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DSME Appointment

Yearly microalbumin

Dilated eye exam in the past

50%

50%

50%

year
Comprehensive foot exam

85%

8 (4.8%)

17 (10.1%)

17 (10.1%)

NS

N=168

N=168

N=168

χ2 = 5.23, p = .07

69 (41.1%)*

81 (48.8%)

102 (61.1%)*

**

N=168

N=168

N=168

χ2 = 17.26, p < .001

43 (25.6%)

54 (32.1%)

54 (32.1%)

NS

N=168

N=168

N=168

χ2 = 2.49, p = .29

41 (24.4%)

62 (36.9%)

47 (28%)

**

N=168

N=168

N=168

χ2 = 8.67, p < .05

*Indicated pair-wise significant differences between time points.
**Indicated overall statistical significance across three time points.

Table 3 Results Summary.
1) There were no significant differences for A1C across Baseline, T2, and T3 (χ2 = 1.38, p =
.50). The proportion of A1C at baseline, T2, and T3 were lower than the benchmark.
2) There were no significant differences for systolic BP across time points (χ2 = 2.80, p
=.25). There were significant differences for diastolic BP across Baseline, T2, and T3 (χ2
= 7.0, p <.05). Post hoc analysis revealed that proportion of diastolic BP (<90 mmHg)
was significantly higher at T3 as compared to the baseline (χ2 = 2.5, p < .05). There was
no significant difference between other time points.
3) There were no significant differences for LDL across Baseline, T2, and T3 (χ2 = 5.15, p =
.08). All the proportion across three time points were higher than benchmark.
4) Overall, there were significant differences for referral to DSME across Baseline, T2, and
T3 (χ2 = 23.16, p < .001). However, there were no significant differences with DSME
referrals (χ2 = 2.37, p = .053) among three time points after Bonferroni correction for
multiple tests. The proportion of DSME across three years was lower than the
benchmark. There were no significant differences for DSME scheduled appointments
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across Baseline, T2, and T3 (χ2 = 5.23, p = .07). Actual DSME appointments were
reviewed by the DNP student. The actual number of patients that went to DSME
scheduled appointments were less than those referred by medical providers for DSME.
5) There were significant differences for Annual Microalbumin across Baseline, T2, and T3
(χ2 = 17.26, p < .001). Post hoc analysis revealed that proportion of Microalbumin was
significantly higher at T3 as compared to the baseline (χ2 = 2.72, p < .01), which was
above the benchmark. There was no significant difference between other time points.
Also, the proportion of Microalbumin at baseline and T2 were lower than the benchmark.
6) There were no significant differences for annual eye exam across Baseline, T2, and T3
(χ2 = 2.49, p = .29). The proportion of annual eye exam at baseline, T2, and T3 were
lower than the benchmark.
7) Overall, there were significant differences for foot exam across Baseline, T2, and T3 (χ2
= 8.67, p < .05). However, there were no significant differences between three time
points after Bonferroni correction for multiple tests. The proportion of foot exam at
baseline, T2, and T3 were lower than the benchmark.
Objective 2: To explore the perceptions and acceptability of the diabetic education accreditation
program (DEAP) team (as measured by Provider Questionnaire), as well as the recommendations
from providers to improve the management of T2DM patient care in the facility and rural
community, both descriptive statistics with demographics of the participants was collected as
well as mixed methods data with Likert scale choices and qualitative responses from open-ended
questions.
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Provider Demographics
A provider questionnaire was sent to 27 primary care providers to evaluate practice
perceptions and acceptability of the DEAP team. Providers were given 2 weeks to complete the
questionnaire, which consisted of multiple choice and open-end responses. Of the 27 providers,
10 completed the questionnaire.
Provider Survey Question Results
Demographics. Demographic. Of 10 eligible providers, 10% were physicians (n=1), 70%
were nurse practitioners (n=7), and 2 were physician assistants (n=2). The overall mean for
providing care for patients with diabetes was 8.80 years (SD=5.90) years, range from 2 to 17
years. Description of responses from providers are as follows: (Appendix C)
Question 1. Of the 10 participants, 80% (n=8) were aware of the type 2 diabetes mellitus
protocol, however 20% (n=2), were unaware of the protocol.
Question 2. Based on a 5-point Likert scale, 70% (n=7) were extremely likely to use the
protocol, 20% (n=2) were likely to use it, and 10% (n=1) were neither likely or unlikely to use
the protocol.
Question 3. An astounding 100% (n=10) participants stated they were aware of the role
of the DEAP team in providing diabetic care.
Question 4. All participants highly rated referral to the DEAP team for education and
patient management. Using a Likert scale 90% (n=9) reported they were extremely likely and
10% (n=1) reported they were somewhat likely to refer to the DEAP team.
Question 5. There was an abundant response of 100% (n=10) participants that felt
COVID-19 had a negative impact on care for patients with diabetes. Using a Likert type scale, of
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10 participants, 40% (n=4) stated they somewhat agree and 60% (n=6) strongly agree on the
affect COVID-19 had on patient care.
Question 6. Provider participants provided responses to the open-ended questions
regarding patient concerns during the COVID-19 pandemic. Several participants stated they felt
COVID-19 negatively affected T2DM patient care due to loss of patient follow-ups and
appointments. One provider stated, “Patients have missed follow ups or opted for telehealth,
often missing out on labs and adjustment of treatment.” Many participants expressed concerns
regarding telehealth visits in place of in-office appointments that “delayed care.” One
participant particularly mentioned missed opportunities for preventative health screenings such
as “Labs, eye exams, foot exams.” One participant described the negative impact on patients
including: “Stress, increased sugars, and sedentary lifestyle increase.”
Question 7. Overall provider participants were aware of the role of the DEAP team. All
participants are knowledgeable in providing type 2 diabetes mellitus care, many noted knowing
about and using the T2DM protocol. They also highly rated referral to the DEAP team for
education and patient management. Several participants expressed concern regarding the care
provided in the last 2 years during the COVID-19 pandemic. However, all participants had
positive suggestions for improving T2DM patient care at the facility and in the surrounding
communities. Notably, almost all participants felt utilization of the DEAP team is vital in the
management of T2DM patient care at the facility and in the surrounding community. One
participant stated, “Our facility does a great job with DEAP; Improve community awareness
advertise our DEAP,” while another participant recommended “Have all T2DM patients have at
least one visit with DEAP.” Many participants felt that the DEAP team should be advertised
more to patients at the facility and in the community, as they do an excellent job at improving
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T2DM patient care. One participant discussed a deeper dive with the DEAP team and extending
care in dietary and exercise education. The participant stated this could be accomplished by
“More access to DEAP at other locations, registered dietician for dietary counseling and even
consideration to eventually add someone to assist with fitness prescriptions and an obesity
management clinic component.” Another participant also mentioned the need for increased
physical activity by harnessing outdoor recreation; “Promote outdoor activity now the weather is
warmer.” All suggestions focused on the improved use of the DEAP team to include more
dietary and physical activity education to patients.
Discussion
Summary
The evaluation of the care patients with T2DM receive was important to provide insight
into systematic quality improvement and improved patient outcomes. This was increasingly
imperative for the future guidance of rural healthcare in southern, West Virginia. The purpose of
this evaluation was to determine the impact of a standardized diabetes mellitus protocol among
patients being treated for diabetes mellitus at a rural, FQHC facility in southern West Virginia.
Interpretation
Objective 1
Hemoglobin A1c Monitoring and Management. There were no statistical differences noted
between baseline and T2 and T3. All hemoglobin A1c results fell short of meeting the facility’s
benchmark goal of 50% of patients with an A1c of <7%. Despite not meeting the goal, at least
42% of patients had a hemoglobin A1c goal of <7%. Diabetes control has been found to be
increasingly difficult during the COVID-19 pandemic. Eberle & Stichling (2021) found that 50%
of publications noted deteriorations in glycemic control. Similarly, Forde et al. (2021) found that
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39% of diabetes patients suffered from acute hyperglycemia during the pandemic. The
“lockdown effect” also contributed to a short-term elevation in hemoglobin A1c levels at 0.3%
among 26% of participants (Biancalana et al., 2020). An article by Scott et al. (2020) also noted
concerns with overall diabetes management during the COVID-19 pandemic. Telehealth was
considered an adequate alternative to in-person visits, as well as continuous glucose monitoring.
Both telehealth visits and increased glucose monitoring have been utilized during the pandemic
at the facility, however despite these alterations, glucose control has been difficult to manage
given the external factors surrounding COVID-19. This may be related to limited internet access
in rural Appalachia.
Diabetes Self-Management Education (DSME) Utilization. Overall, there were
findings of significant differences for referral to DSME across Baseline, T2, and T3. However,
there were no significant differences with DSME referrals among three time points after
Bonferroni correction for multiple tests. There were also no significant differences for patients
attending DSME appointments across Baseline, T2, and T3. Although the proportion of DSME
referrals and patient attended appointments across three years were lower than the benchmark of
50%, there were positive changes with initiation of the DEAP team in 2020. Prior to DEAP
initiation at baseline in 2019, only 4.8% of patients received DSME. In T2, this rose to 22%,
however dropped to 14.9% in T3. There were more patients referred to DSME in T2, than in T3.
This may be due to the initial creation and support for use with advertisement of the DEAP team
and facility in 2020. An expected finding was that the actual number of patients that went to
DSME scheduled appointments were less than those referred by medical providers for DSME.
However, the same number of patients attended DSME appointments at T2 and T3(10.1%). This
infers an overall improved compliance to DSME referral and appointment over time. Despite not
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achieving the benchmark goal and slightly less referrals in T3 than initially in T2, there is
improvement in the number of patients attending DSME. This may be related to increased
patient-provider rapport, DEAP feedback and patient reviews, COVID-19 pandemic decline with
vaccination availability, community awareness, etc.
Forde et al. (2021) found that COVID-19 had a significant impact on both physical and
psychological problems for diabetic patients. The data found that diabetes education and
management was extremely or quite severely disrupted during the pandemic. However, with
COVID-19 infection rates on the decline, there is hope that DSME appointments will increase
with resultant improvement in the care diabetes patients receive. Without the pandemic as a
cofactor, DSME is high effective in improving glycemic control, lipids, and BMI, while
moderately improving blood pressure management in a study by Mikhalel et al., 2020.
Blood Pressure Monitoring and Management. Despite there being no significant
differences for systolic BP across all time points, all time frames exceeded the facility’s
benchmark goal of 50% of patients achieving a systolic blood pressure of <140mmHg. Around
75% of patients achieved the goal at baseline, and over 80% achieved the goal at T3. This is a
great improvement with sustained findings over the time frame of evaluation. There were
significant differences for diastolic BP across Baseline, T2, and T3. Post hoc analysis revealed
that proportion of diastolic BP (<90 mmHg) was significantly higher at T3 as compared to the
baseline. Over 97% of patients met the facility benchmark goal, showing significant control of
diastolic blood pressure.
Dyslipidemia Assessment and Control. Like blood pressure analysis, LDL did not show
significant differences across Baseline, T2, and T3. However, all data points across three time
points were higher than benchmark of 50% of patients meeting an LDL of <100 mg d/L. The
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highest number of patients meeting this goal was surprisingly at T2 during the beginning of the
of COVID-19 pandemic. However, T2 also had the least number of patients having laboratory
evaluations of LDL. A study by Psoma et al. (2020) similarly found no significant difference in
LDL levels throughout the pandemic, and surprisingly found a decrease in overall hemoglobin
A1c, total cholesterol and BMI levels. This was contributed to more time to attend appointments,
exercise, and have healthier diet for people with time consuming work responsibilities prepandemic. This could be a direct correlation with the clinic findings in this study.
Urine Microalbumin or Albumin to Creatinine Testing for Diabetic Nephropathy.
There were great improvements noted with annual microalbumin and significant differences
across Baseline, T2, and T3. Post hoc analysis revealed that proportion of microalbumin was
significantly higher at T3 as compared to the baseline. Baseline and T2 time frames were below
the facility benchmark of 50% of patients meeting the measure of having an annual
microalbumin. There was a 20% overall increase from baseline to T3, in which T3 was greater
than the benchmark goal at 61.1%. This measure may also have been improved by the DEAP
team’s ability to order testing for provider’s if laboratory testing were due.
Foot Screening for Diabetic Nephropathy. Overall, there were significant differences
for foot exams across Baseline, T2, and T3. There was noted improvement from 24.4% at
baseline to 36.9% at T2 and slightly lower again at 28% at T3. The proportion of foot exams at
baseline, T2, and T3 were lower than the benchmark of 85%. The number of patients receiving
foot examinations for peripheral neuropathy could have been improved by the DEAP team’s
sponsoring of foot examinations and ordering of diabetic shoes via partnership with a podiatrist
that evaluates patients at the main facility. As mentioned above, the main clinic in houses most
of the patient population served by the facilities, thereby providing a large sample population.
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This is also one of the more rural locations. Prior to the DEAP program’s collaboration with
podiatry, the closest specialist was located at least 30 minutes from the main facility. This
limited access to care for many elderly, low-income, and underserved patients.
Overall, four of the seven CQM’s met facility benchmarks, while two (diastolic blood
pressure and microalbumin) had statistically significant results at T3. Improvements are under
way for many of the measures that were below facility benchmarks, and future guidance will be
made with dissemination of results. The Charlson Comorbidity Index was used to provide a
better understanding of the most common comorbidities seen at the facility and evaluate what
may be important to focus on in the future. Most patients had at least one other comorbidity with
a few of the most common being COPD, MI, CVA, and CHF. For example, over 35% of patients
had a diagnosis of end organ damage with T2DM and nearly 20% had COPD. The patients
require a high level of care, and some may have been afraid to come into the facility for visits
due to COVID-19. It is thereby important for the facility to focus on control of measures such as
blood pressure, cholesterol levels, and hemoglobin A1c’s to prevent worsening of these
diagnoses.
Annual Dilated Eye Exam Screening for Diabetic Retinopathy. The proportion of
patients receiving an annual retinal eye exam at baseline, T2, and T3 were lower than the
benchmark of 50%. Despite this, there was improvement noted from baseline to T2 and T3, with
an increase of nearly 7%. There were no significant differences for annual eye exam across
Baseline, T2, and T3 (T2 and T3 both have 32.1%). The low number of patients receiving annual
retinal eye examinations may be related to multiple factors. The first includes the lack of
available resources of optometrists/ophthalmologists near the facilities during the time frame of
analysis. There is only one specialist within 30 minutes of the main facility location, which
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houses many of the facility’s patients. Certain providers also may not accept the patient’s
insurance further limiting their access to care. This has since been improved with access to
annual screenings at the main facility location, and possibly soon to other facility locations. This
allows patients to receive an annual retinal eye examination the same day as their regular followup appointment.
Second, data retrieval may also be an issue with evaluation. If a patient’s records are not
received, the patient may not be counted as having the eye exam for that year. Finally, data input
is a major concern for accurate data retrieval and evaluation. Until recently, eye exams were
listed under health maintenance as “annual eye exam,” by most staff. This, form of wording
however did not count toward our number of patients receiving the examination. It instead must
be documented as “retinal eye exam,” to receive credit. This, however, did not impact this study,
as the student ran a manual chart review and utilized all eye exam documentation; “annual eye
exam” and “retinal eye exam,” as listed in the chart.
Objective 2
All participants were aware of the role of the DEAP team in providing diabetes care.
They highly rated referral to the DEAP team for education and patient management. A
systematic review by Mikhail et al. (2020) reiterates the success of DSME with improvement
noted in all clinic outcomes (hemoglobin A1c, fasting and non-fasting glucose readings, total
cholesterol and triglycerides, and BMI) in at least 60% of the studies. All patients reported
improved self-management, knowledge, and outcomes as well. Norris et al. (2002), similarly
reports improvement in hemoglobin A1c levels at 0.76% at immediate follow-up, 0.26% at 1-3
months, and 0.26% greater than 4 months after DSME. This suggests that engaging stakeholders
in the quality improvement from the design to implementation enhance the sustainability of
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learned behaviors change over time and may be improved with prolonged or recurrent DSME for
maintaining glucose control. A recommendation for future studies would be to further evaluate
the effectiveness of DSME over a prolonged period to sustain and improve quality of care over
time. This includes implementation of continuous quality improvement projects and evaluation,
promotion of leadership with the DEAP team, and making the program visible to all staff
members to promote referrals.
Notably, almost all participants felt utilization of the DEAP team is vital in the
management of T2DM patient care at the facility and in the surrounding community. Participants
were given the opportunity to use an open-ended response for this question to elaborate on
T2DM management needs. All participants had positive suggestions for improving T2DM
patient care at the facility and in the surrounding communities. Barriers to DSME should be
explored to promote awareness and improved utilization to improve outcomes, as it is a
universally recommended tool to improved diabetes management. Coningsby et al. (2022)
evaluated such barriers to DSME by use of Andersen’s Behavioral Model of Health Service
Utilization as a framework. After 2 years of data, they found “perceived barriers” to include a
lack of knowledge about the program and need for education. They also found “practical
barriers” such as transportation issues and other commitments limiting time. The study
concluded that barriers need to be assessed on an individual basis to improve access to care and
promote awareness. A study by Ndjaboue et al. (2020) analyzed expert patients’ knowledge and
wisdom to improve diabetes care. The patients similarly felt diabetes management can be
improved by individual care plans and group collaboration with open communication by the
provider. These suggestions will be provided to the stakeholders during project presentation.
Similarly, the clinic had individual barriers (patient level) that include lack of transportation, and
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poor access to care including internet. Practical barriers may include provider utilization of the
DEAP team due to poor patient adherence, limited access at satellite clinics, and lack of
knowledge regarding outcomes associated with use. System level barrier may include poor
advertisement, and lack of support to increase providers at satellite clinics and improve access to
care.
Limitations
The worldwide COVID-19 pandemic took precedence in 2020. Agency resources were
distributed in other more pressing clinical areas, delaying the ability to conduct program
evaluation as planned at 12 months. With clinic flow mostly returning to pre-COVID-19 ways,
administration has now granted approval for program evaluation to begin. The author, who is a
nurse practitioner at the facility and a Doctor of Nursing Practice student at West Virginia
University, lead the evaluation. Data collection commenced in February 2022; thus, the
evaluation was expanded to include two years of outcomes, rather than the original first year.
This evaluation project served as the author’s doctoral capstone project and has been approved
by facility leadership (Appendix E).
This project brought important program information to the agency, the people they serve,
led by, and leveraging the skill set of the doctoral prepared nurse. Program evaluation provided
the facility with valuable information in their pursuit to standardize care and reduce the burden
of disease. It also assists them in establishing a road map for program expansion or remediation.
Doctoral prepared nurses are aptly positioned to conduct program evaluation, given their
expertise in management of chronic conditions, program development and evaluation.
Limitations include DEAP team relocation. The DEAP team was relocated to other job
positions during the height of pandemic which limited utilization in 2020. This may have
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contributed to low DSME utilization as well as other CQM’s below benchmark percentages.
Another limitation was the small sample size seen on the provider survey. This could be
attributed to poor communication for the reason of evaluation (since this is the 1st evaluation),
time, or lack of reward for completion. We also recently had changes in the email system d/t
outside emails containing viruses, which may have contributed to provider uncertainty with
clicking the link for the survey. Measures could also be collected over discrete time frames such
as quarterly or monthly to limit changes seen over variable time frames throughout the year.
Conclusion
Diabetes is a challenging health condition that affects many Americans. Standardized
protocols and methods have improved T2DM treatment. As health care systems strive to
implement best practices in diabetes care, it is also incumbent on them to evaluate their
implementation efforts. Much can be learned through the process of evaluation. For the facility,
adopting a standardized approach to care has been a comprehensive effort to improve population
health. Program evaluation completes the cycle, providing the facility with valuable information
to inform their future practices and care of persons with T2DM.
Core quality measures were reviewed using continuous and dichotomous variables over
T1, T2, and T3 time periods. Hemoglobin A1c, systolic blood pressure, LDL, referral to DSME,
patient appointments to DSME, annual neuropathy and retinopathy findings were not statistically
significant across the three-time frames evaluated. Diastolic blood pressure and annual
microalbumin had statistically significant improvement at T3. Despite limited statistically
significant improvement regarding core quality measures, almost all measures showed
improvement from T1 to T3. Provider behaviors also correlated with compliance with the
utilization of DSME and diabetes protocol driven care. Despite the COVID-19 pandemic, the

52
facility had noted overall diabetes management and patient care outcome improvement over the
evaluation time frames.
The provider questionnaire concluded that most providers were aware of the diabetes
protocol and the DEAP team. Majority of the providers were extremely likely to refer to the
DEAP team for diabetes patient management. All providers felt that the COVID-19 pandemic
negatively affected patient outcomes and provided responses for improving diabetes
management including increased access to care via use of DSME. This will serve as a guideline
to the facility in future diabetes patient care management and evaluation.
Recommendations
Future recommendations include the evaluation of core quality measures over a time
frame after the COVID-19 pandemic effect lessens. The results during the pandemic have
provided vital data, however, has also served as an external factor influencing outcomes of the
new diabetes protocol and DEAP team creation in providing care. Appointments were limited
despite the use of telehealth, due to many issues including cost, transportation, fear of illness,
and poor access to care including internet usage. Patients had different eating habits, exercise
management, and medication adherence during this time like never before. This could have
contributed to limited improvement in core quality measures. Core quality measures could be
added to include pneumonia vaccination and medication adherence to angiotensin converting
enzyme (ACE) inhibitor, angiotensin II receptor (ARB) blockers, and/or statin use. Finally, core
quality measure percentages should be adjusted based on the results of this evaluation to provide
attainable, yet challenging benchmarks. Promoting achievements of such goals could also be
promoted through use of a reward system for providers and staff.

53
Implications for Practice
Update Benchmarks. Over half of the measures were found to appraise above the
facility benchmarks. Recommendations include increasing benchmark percentages to new,
challenging levels, and providing encouraging feedback to providers for areas of practice within
the protocol that were successful such as blood pressure, LDL, and urine microalbumin
monitoring and management. Also, it would be recommended to consider a reward system for
providers and/or by facilities.
Blood pressure, LDL cholesterol, and urine microalbumin screening and management
were among the highest percentages of outcome measures noted in the evaluation. Possible
rationales for this are described below. Blood pressure has long been a measure of interest of the
facility with the use of various interventions, including Target BP. Target BP is a program in
which the facility loans machines and logs to patients for home use while changing medications
or gaining control. There are also various patient education and posters in the rooms, provider
feedback and adherence by the quality improvement team on use of ACE/ARBs, and newly
integrated EHR prompts to document control. Blood pressure may also be more easily
understood and a concern of patients, as the see it as a ‘real problem.’
LDL cholesterol is often also seen a problem by patients. Most patients are adherent to
some form of cholesterol lowering treatment such as diet or medication. Many providers also
recommend and verify the benefit in using medications such as statins to prevent comorbidities.
Urine microalbumin is a measure that has recently improved at the facility, as evidenced
by the evaluation. All patients with T2DM are recommended to have regular labs every 3 to 6
months, giving providers to the ability to discuss the need of urine microalbumin monitoring for
the early detection of chronic kidney disease. There is an ease of testing and many providers
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have also seen the need to improve facility metrics in this area. Over 35% of patient had findings
of target organ damage during the evaluation, creating an initiative for providers to promote
regular testing.
Promote Patient Education and Self-Management with an Individualized Care Plan.
There were findings of low DSME/DEAP referral and patient follow-up throughout the
evaluation time frames. This could be associated with new utilization of the protocol and
creation of the DEAP team. Recommendations include increased education to providers and
patients about the utilization of the DEAP team at the facility. This may include regular referral
recommendations installed into the EHR as prompts, flyers, Facebook ads, and more. Also, a
recommendation would be to expand DEAP providers, if possible, to other satellite clinics to
improve transportation concerns with patients.
Patient-Centered Approach to Hemoglobin A1c Control. Hemoglobin A1c control
was slightly below the benchmark of 50% at all time frames. This could be improved by use of
the DEAP team that includes a a personalized approach to increase education. Creation of a
guideline for DSME patient referral (for example new diagnosis, hemoglobin A1c >9%, annual
visits, or newly uncontrolled patients) could be beneficial. Use of telehealth visits versus in
patient visits would be interesting to evaluate to determine outcomes and patient compliance.
Group meetings have also been discussed to provide a support system for patient with T2DM. A
patient survey may be beneficial to further understand the best approach. Use of Dexcom trials
(continuous glucose monitoring [CGM]) are being utilized now to find trends and improve
understanding of each patient’s individual control and are integral in improving diabetes control.
Address Barriers to Care. Retinopathy and neuropathy exams were among the lowest
measures across the timeframes. Reasoning for this may include rural location with limited
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access to care. Retinal eye exams are now available at the main clinic site along with foot exams
via podiatry with ordering of diabetic shoes. There is a need to consider expanding such services
to satellite clinics to improve adherence, specifically to locations that have limited providers.
Expand Care with Provider and Patient Engagement. Expansion of care to as many
patients as possible was found to be a popular response by providers on the survey.
Recommendations for regular use of the DEAP team was also made by majority of providers. A
recommendation for future patient engagement includes seeking a more informed understanding
of ways to incorporate patient responses and answer questions/concerns for reasoning not to refer
to the DEAP team.
Ensure Long-Term Follow-Up. A major key factor in the care of patients with diabetes
included the COVID-19 pandemic. All providers felt it caused poor outcomes in patients
including lack of visits, missed labs and screenings, and poor diet and exercise. As COVID-19
declines, providers and staff need to reach out to patients that have missed appointments and try
to catch up on needed visits/screenings. This is currently being done by nursing, and quality
improvement team leaders at the facility.
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Doctor of Nursing Practice Essentials
The Doctor of Nursing Practice (DNP) essentials are a vital aspect of the study. The DNP
essentials provide clarity and guidance in keeping with the promotion of population health and
wellness in the diabetes community. The project includes the eight core essentials and are
discussed below (American Association of Colleges of Nursing, 2006).
I - A scientific background of the current facility’s T2DM protocol utilizing the ADA 2018 and
AACE 2015 recommendations
II - Organizational leadership via the creation of an evaluation tool for diabetes management
III - Integration of evidence-based practices utilizing established evaluation practices (CDC
Program Evaluation Tool)
IV - Technology utilization of the AZARA data analyzation, Excel spreadsheets, teams email
system
V - Avocation and institution of systems level policy change for annual evaluation of the current
diabetes protocol
VI - Interprofessional collaboration among all members of the healthcare team via the Chronic
Care Model
VII - Health promotion and disease prevention by creation of an evaluation tool for an
underserved, rural population of T2DM patients
VIII - Advancement of nursing practice by leveraging the skill set of the doctoral prepared nurse
in chronic disease management, program evaluation, change leadership, and dissemination of
findings through scholarly publications and presentations. DNP-led diabetic evaluation of current
guidelines and future recommendations to improve clinician knowledge and holistic patient
outcomes
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Appendix A
Facility Diabetes Care Protocol
Clinical Goal: To reduce unnecessary death and disability from diabetes
Description: In an effort to reduce unnecessary morbidity and mortality from diabetes and its
complications, the clinic utilizes the current American Diabetes Association Standards of
Medical Care in Diabetes for the prevention, diagnosis and treatment of diabetes and its related
complications.
Methods:
1.

Diagnosis:
A. Diabetes
I. Criteria for the diagnosis for non-pregnant patients in stable state (not
acutely ill)
1. Fasting plasma glucose (FPG) ≥ 126 mg/dl
2. Random plasma glucose ≥ 200 mg/dl with symptoms of
hyperglycemia
3. Plasma glucose > 200 mg/dl 2 hours after 75-gram oral glucose
tolerance test (OGTT)
4. Hemoglobin A1c ≥ 6.5%
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II. For FPG and OGTT, patients ingest no calories for at least 8 hours prior to
testing, and should have adequate carbohydrate intake for several days prior to test
III. Diagnosis of diabetes should be confirmed on a different day
B. Pre-diabetes
I. Impaired Fasting Glucose (IFG) defined as FPG 100 to 125 mg/dl
II. Impaired Glucose Tolerance (IGT) defined as plasma glucose 140-199 mg/dl 2
hours after OGTT
III. Category of increased risk for diabetes
1. HBA1c 5.7 to 6.4%
C. Screening
I. All adults ≥ 45 years of age
II. All adults with BMI ≥ 25 kg/m2 with additional risk factors for diabetes
III. The American Academy of Pediatrics and ADA recommend screening all
obese children with additional risk factors for T2DM (i.e. positive family history,
non-white race, acanthosis nigricans, etc.) on physical examination
2.

Newly diagnosed people with diabetes
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A. A complete physical exam should be performed along with lab work-up to include a
urinalysis, urine microalbumin, complete metabolic profile (CMP), fasting lipid panel,
hemoglobin A1c, and EKG if over 40 years of age
B. Dietary and lifestyle education, including self-management goals, should be given and
documented
C. Blood Pressure (reference Hypertension Protocol)
I. Blood pressure should be measured at every routine clinical visit.
II. Patients found to have elevated blood pressure (≥140/90) mmHg should have
blood pressure confirmed using multiple readings, including measurements on a
separate day, to diagnose hypertension
1. All hypertensive patients with diabetes should be encouraged to monitor
their blood pressure at home
2. For patients with blood pressure >120/80 mmHg, lifestyle intervention
consisting of weight loss if overweight or obese; a Dietary Approaches to
Stop Hypertension (DASH)–style dietary pattern including reducing
sodium and increasing potassium intake; moderation of alcohol intake;
and increased physical activity should be encouraged
D. Lipid Management (reference Lipid Management protocol)
1. Lifestyle modification focusing on weight loss (if indicated); the
reduction of saturated fat, trans fat, and cholesterol intake; increase of
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dietary n-3 fatty acids, viscous fiber, and plant stanols/sterols intake; and
increased physical activity should be recommended to improve the lipid
profile in patients with diabetes
2. All patients with diabetes and atherosclerotic cardiovascular disease,
high-intensity statin therapy should be added to lifestyle therapy
3. For patients with diabetes aged <40 years with additional
atherosclerotic cardiovascular disease risk factors, the patient and provider
should consider using moderate-intensity statin in addition to lifestyle
therapy
4. For patients with diabetes aged 40-75 years and >75 years without
atherosclerotic cardiovascular disease, use moderate-intensity statin in
addition to lifestyle therapy
II. Type 2 diabetes (see algorithm for treatment of type 2 diabetes; Standards of
Medical Care in Diabetes page S76)
1. Metformin, if not contraindicated and if tolerated, is the preferred initial
pharmacologic agent for the treatment of type 2 diabetes
2. A patient-centered approach should be used to guide the choice of
pharmacologic agent. Considerations include efficacy, hypoglycemia risk,
history of atherosclerotic cardiovascular disease, impact on weight,
potential side effects, renal effects, delivery method (oral vs
subcutaneous), cost and patient preferences
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3. Consider initiating insulin therapy (with or without additional agents) in
patients with newly diagnosed type 2 diabetes who are symptomatic and/or have
A1C ≥ 10% and/or blood glucose levels ≥ 300 mg/dl
4. Consider initiating dual therapy in patients with newly diagnosed type 2
diabetes who have A1C ≥ 9%
5. A patient-centered approach should be used to guide the choice of
pharmacologic agent. Considerations include efficacy, hypoglycemia risk,
history of atherosclerotic cardiovascular disease, impact on weight,
potential side effects, renal effects, delivery method (oral vs
subcutaneous), cost and patient preferences
F. Consideration for referral to a Diabetes Educator (CDE) for Diabetes SelfManagement training (DSMT), Registered Dietician (RD), or Certified Nutrition
Specialist (BCNS) should be encouraged.
G. Referral for a diabetic eye exam
H. A prescription for testing of blood glucose levels at home should be provided.
Prescription for testing equipment should include: blood glucose meter, blood glucose
testing strips, lancing device, lancets, and control solution
I. Target goal for A1C should be less than 7% in most patients and consider less than
6.5% in those healthy patients with low risk of complications. Individualized A1C 8% or
greater may be considered for frail patients
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J. Follow-ups should be at least at 3-month intervals until glucose is stable, and should
include A1C if not done in past 3 months
3. Established people with diabetes
A. Office visits every three months with a review of home blood glucose logs. More
frequent visits may be warranted if patient is symptomatic, or abnormalities exist in lab
tests
B. Reinforce exercise and diet education, including self-management goals, at least
annually
C. Document foot exam and education for patient to do daily foot exam every routine
visit
D. Diabetes pharmacologic treatment evaluation
I. In patients without atherosclerotic cardiovascular disease, if monotherapy or
dual therapy does not achieve or maintain the A1C goal over 3 months, add an
additional antihyperglycemic agent based on drug-specific and patient factors
II. A patient-centered approach should be used to guide the choice of
pharmacologic agent. Considerations include efficacy, hypoglycemia risk, history
of atherosclerotic cardiovascular disease, impact on weight, potential side effects,
renal effects, delivery method (oral vs subcutaneous), cost and patient preferences
III. In patients with type 2 diabetes and established atherosclerotic cardiovascular
disease, antihyperglycemic therapy should begin with lifestyle management and
metformin and subsequently incorporate an agent proven to reduce major adverse
cardiovascular events and cardiovascular mortality (currently empagliflozin and
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liraglutide, but other agents currently being studied), after considering drugspecific and patient factors
IV. In patients with type 2 diabetes and established atherosclerotic cardiovascular
disease, after lifestyle management and metformin, the antihyperglycemic agent
canagliflozin may be considered to reduce major adverse cardiovascular events,
based on drug-specific and patient factors
V. Continuous reevaluation of the medication regimen and adjustment as needed
to incorporate patient factors and regimen complexity is recommended
VI. For patients with type 2 diabetes who are not achieving glycemic goals, drug
intensification, including consideration of insulin therapy, should not be delayed
VII. Metformin should be continued when used in combination with other agents,
including insulin, if not contraindicated and if tolerated
E. Diabetes and hypertension (see page s90 of Standards of Medical Care in Diabetes2018 for chart)
I. Most patients with diabetes and hypertension should be treated to a systolic
pressure goal of <140 mmHg and a diastolic blood pressure goal of <90 mmHg
II. Lower systolic and diastolic blood pressure targets, such as 130/80 mmHg,
may be appropriate for individuals at high risk of cardiovascular disease, if they
can be achieved without undue treatment burden
III. Lifestyle modification should be evaluated and reinforced
IV. Patients with confirmed office-based blood pressure >160/100 mmHg should,
in addition to lifestyle therapy, have prompt initiation and timely titration of two

74
drugs or a single-pill combination of drugs demonstrated to reduce cardiovascular
events in patients with diabetes
V. Treatment for hypertension should include drug classes demonstrated to reduce
cardiovascular events in patients with diabetes (ACE inhibitors, angiotensin
receptor blockers, thiazide-like diuretics, or dihydropyridine calcium channel
blockers)
VI. Multiple-drug therapy is generally required to achieve blood pressure targets.
However, combinations of ACE inhibitors and angiotensin receptor blockers and
combinations of ACE inhibitors or angiotensin receptor blockers with direct renin
inhibitors should not be used
VII. An ACE inhibitor or angiotensin receptor blocker, at the maximally tolerated
dose indicated for blood pressure treatment, is the recommended first-line
treatment for hypertension in patients with diabetes and urinary albumin-tocreatinine ratio ≥300 mg/g creatinine or considered in those with values 30–299
mg/g creatinine.
VIII. If one class is not tolerated, the other should be substituted
IX. For patients treated with an ACE inhibitor, angiotensin receptor blocker, or
diuretic, serum creatinine/estimated glomerular filtration rate and serum
potassium levels should be monitored at least annually
F. Yearly funduscopic exams
G. Yearly microalbumin urine, repeat in 3 months if abnormal. Any patient with
persistently abnormal urine microalbumin will be referred to nephrology for further
evaluation. If possible, stop any diuretic after first abnormal microalbumin
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H. HBA1C done every 3 to 6 months depending upon how well diabetes is controlled
I. Lipid management
i. Reinforce lifestyle modification
ii. Intensify lifestyle therapy and optimize glycemic control for patients with
elevated triglyceride levels (≥150 mg/dl and/or low HDL cholesterol (<40mg/dl
for men, <50 mg/dl for women))
iii. Provider may need to consider adjusting intensity of statin therapy based on
individual patient response to medication (e.g. side effects, tolerability, LDL
cholesterol levels, or percent LDL reduction on statin therapy). For patients who
do not tolerate the intended intensity of statin, the maximally tolerated statin dose
should be used
iv. For patients with diabetes and atherosclerotic cardiovascular disease, if LDL
cholesterol is ≥70mg/dl on maximally tolerated statin dose, consider adding
additional LDL-lowering therapy (such as ezetimibe or PCSK9 inhibitor) after
evaluating the potential for further atherosclerotic cardiovascular disease risk
reduction, drug-specific adverse effects, and patient preferences.
J. Antiplatelet agents
I. Consider aspirin therapy (75-162 mg/day) as a secondary prevention strategy in
those with diabetes and a history of atherosclerotic cardiovascular disease
II. Aspirin therapy (75-162 mg/day) may be considered as a primary prevention
strategy in those with type 1 or type 2 diabetes who are at increased
cardiovascular risk. This includes most men and women with diabetes aged ≥ 50
years who have at least one additional major risk factor (family history of
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premature atherosclerotic cardiovascular disease, hypertension, dyslipidemia,
smoking, or albuminuria) and are not at increased risk of bleeding.
III. Clopidogrel may be used in documented aspirin allergy
K. Non-compliant patients or those on multiple medications with no substantial change in
A1C, should be considered for referral to endocrinology.

How Often to Audit: annually

How Many Charts to Audit: 10 per FTE

Identify Charts: Random screen from Electronic Health Record (EHR) of people with
diabetes who are active users

Acceptable Levels of Compliance:
Average HgbA1C <7%: 50%
Documented self-management counselling within the last year: 50%
BP Controlled <140/90: 50%
LDL less than 100 mg/dL: 50%
Yearly microalbumin: 50%
Dilated eye exam in past year: 50%
Comprehensive foot exam documented at all routine follow-up appointments: 85%
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Appendix B
SWOT Analysis
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Appendix C
Provider Questionnaire : Perceptions and Recommandations
a. Please identify your role: (1) physician (2) nurse practitioner (3) physician assistant (4)
Other, please specify_______
b. How long have you been providing diabetic care and treatment: ______ years.
Please select the best answer.
1. Are you aware of the facility’s type 2 diabetes mellitus (T2DM) protocol?
a. Yes
b. No
2. How likely are you to utilize the T2DM protocol in practice?
a. Extremely likely
b. Likely
c. Neutral
d. Not likely
e. Never
3. Are you aware of the role of the diabetic education accreditation program (DEAP) team?
a. Yes
b. No
3.1 If answer No, please explain why not?
4. How likely are you to refer to the DEAP team for patient education/management?
a. Extremely likely
b. Likely
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c. Neutral
d. Not likely
e. Never
5. Do you think the COVID-19 pandemic has negatively affected T2DM patient care in the
past 2 years?
a. Yes
b. No
5.1. If you answered yes, how strongly has it affected T2DM care?
•

Strongly agree

•

Agree

•

Neutral

•

Disagree

•

Strongly disagree

6. Please describe briefly how the COVID-19 pandemic has negatively affected T2DM
patient care (Open-ended, short response): _________________________
7. How can we improve the management of T2DM patient care in our facility and rural
community? (Open-ended, short response) __________________
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Appendix D
Budget
Budget Categories

Personal Funds

Organizational
Contributions

ADMINISTRATIVE COSTS

$0

~$4,280

Cost of evaluation study for staff is covered under current salary. It was estimated that the
team leader at the facility collected the data at an average rate of ($50 per hour). There were
around 40 hours spent on data collection and provider survey distribution. The cost for 40
hours of time spent by the team champion nurse practitioner on completing the data
collection is estimated to be $2,000. The team leader nurse practitioner average rate of ($50
per hour), 2 pharmacists – 2 DEAP team members ($65 per hour), 1 registered nurse –
DEAP member ($30 per hour), and 1 receptionist – DEAP member ($18 per hour) was
utilized for time spent for meetings. The average time spent for meetings of staff members
was estimated at 10 hours; the team champion nurse practitioner (~$50/hour) , and 4 DEAP
members (x2 ~$65, x1 ~$30, x1~$18) to equal about $2,280.
MARKETING

$0

$0

$15

$0

No funds necessary.
EDUCATIONAL MATERIALS/
INCENTIVES
Cost of Zoom meeting upgrade for DNP defense.
Budget Categories

Personal Funds

Organizational
Contributions
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PROJECT SUPPLIES (office
$0

$50

supplies, postage, printing, etc.)
$50 estimated to print reports from Qualtrics.

OTHER

$0

$0

$15

~$4,330

Other: No other costs associated.
TOTALS
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Project Approval
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Appendix F
Medical Record Review Template
De-identified Medical Review
Demographic:
Sex ____ Male _____Female
Age ______years
Length of diabetes mellitus diagnosis ____ years
Core Quality Measures
Average hemoglobin A1C <7%
Documented self-management counseling
within the last year
BP controlled <140/90
LDL <100mg/Dl
Yearly microalbumin
Dilated eye exam in the past year
Comprehensive foot exam documented at
all routine follow-up appointments

Baseline
(T1)
Value
Value

T2

T3

value
value

Value
Value

Value
Value
Value
Value
Value

value
value
value
value
value

Value
Value
Value
Value
Value

Note: These include type 2 diabetes mellitus diagnosis codes (ICD-10). Diabetes diagnosis,
retinopathy, nephropathy, and neuropathy exams will be reported by a positive or negative
finding in the chart for the specified periods.
Charlson Comorbidity Checklist: Does patient have the following diagnosis in the medical
records? If yes, check X
_____Diabetes Mellitus (must check)
_____ Myocardial infarction
_____ Peripheral vascular disease
_____ Cerebrovascular disease or TIA
_____ Dementia (Exclusion Criteria)
_____Congestive Heart failure
_____ Diabetes with end organ damage
_____ Chronic pulmonary disease
_____ Connective tissue disease
_____ Moderate/severe renal disease

_____ Hemiplegia
_____ Ulcer disease
_____ Mild liver disease
_____ Moderate/severe liver disease
_____ Any malignancy
_____ Metastatic solid malignancy
_____ Leukemia
_____ Malignant Lymphoma
_____AIDS
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Appendix G
Cover Letter
Dear Prospective Participant,
This letter is a request for you to participate in a research project Evaluation of a
Comprehensive Diabetes Mellitus Protocol at a Rural, Federally Qualified Health Center in
Southern West Virginia. This project is being conducted by Hannah Davis, MSN, APRN, FNPC in the School of Nursing at WVU under the supervision of Dr. Ubolrat Piamjariyakul, PhD,
RN, an Associate Dean of Research and Scholarship at WVU in the School of Nursing, to fulfill
requirements for the degree of Doctor of Nursing Practice.
If you decide to participate, you will be asked to complete an anonymous, online survey. Your
participation in this project will take approximately 10-15 minutes. All participants must be
primary care providers at the clinic being evaluated. You must be 18 years of age or older to
participate. You will not receive any direct benefits or incentives for your participation in the
study.
Your participation in this project will be kept as confidential as legally possible. Your
involvement is anonymous. All data will be reported in the aggregate. You will not be asked any
questions that could lead back to your identity as a participant. Your participation is entirely
voluntary. You may skip any question that you do not wish to answer, and you may stop
participating at any time. Your employment status will not be affected if you decide not to
participate or withdraw. West Virginia University Institutional Review Board's approval of this
project is on file with the WVU Office of Human Research Protections.
If you have any questions about this research project, please feel free to contact me at 304-4386188 (ext. 1064) or by email at hdhellems@mix.wvu.edu or Ubolrat Piamjariyakul
(ubolrat.piamjariyakul@hsc.wvu.edu), supervising faculty. Additionally, you can contact the
WVU Office of Human Research Protections at 304-293-7073.
I hope that you will participate in this research project, as it could help us better understand the
impact of a standardized diabetes mellitus protocol, the providers’ perceptions and acceptability
of the diabetic education accreditation program (DEAP) team, and recommendations to improve
the management of diabetes patient care in the facility and rural community. Thank you for your
time and consideration.
Sincerely,

Hannah Davis, FNP-C

